AAV has gained popularity in recent years as a tool for gene therapies. AAV is a replication-deficient, capsid virus. The advantage of AAV is that the virus is very stable.

AAV can be made by transient transfection in mammalian cells.

AAV can also be made using baculo expression system.

LakePharma provides engineering and process development solutions for AAV. Can do both mammalian transient and baculo expression system. Can't do GMP manufacturing yet due to lack of GMP facility dedicated to viral vector manufacturing.